To evaluate the efficacy and safety of albuterol delivered via a novel, inhalation-driven, multidose dry powder inhaler (MDPI) that does not require patient coordination of device actuation with inhalation and albuterol hydrofluoroalkane (HFA) at 2 dose levels relative to placebo in children with persistent asthma. Methods: A phase 2, multicenter, double-blind, doubledummy, single-dose, 5-period, crossover study (ABS-AS-202; NCT01899144) randomized pediatric patients (aged 4 11 years) with persistent asthma and prestudy forced expiratory volume in 1 second (FEV 1 ) of 60% 90% of predicted normal to 1 of 10 treatment sequences containing albuterol MDPI (90 and 180 mcg), albuterol HFA (90 and 180 mcg), and placebo MDPI+placebo HFA. Spirometry was the primary measurement to evaluate study end points. Serial FEV 1 measurements were obtained at designated time points over 6 hours after the completion of study drug administration at each treatment visit. Safety was evaluated by adverse events. Results: The full analysis set included 61 patients. Baseline-adjusted percent-predicted FEV 1 -time curve over 6 hours postdose (PPFEV 1 AUC 0-6 ) was significantly greater in all active treatment groups compared with placebo (P Table) . PPFEV 1 AUC 0-6 was similar in the albuterol MDPI 90 mcg and 180 mcg groups (Table) ; however, the albuterol HFA 180 mcg group had significantly greater PPFEV 1 AUC 0-6 than the albuterol HFA 90 mcg group (P=0.0226; Table) . All doses of albuterol were generally well tolerated. Conclusions: Albuterol MDPI significantly improved pulmonary function versus placebo in children with asthma. Improvements for albuterol MDPI 90 and 180 mcg were similar; a dose-response effect was observed with albuterol HFA. Results suggest that relief of asthma symptoms in children may be managed adequately with albuterol MDPI (1 2 inhalations). No new safety concerns were noted with albuterol MDPI, and its safety profile is consistent with that of albuterol HFA.
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